Precision engineered with the goal of targeting disease
Currently, surgery is a primary treatment modality for a large number of solid cancers, and published literature shows that for many of these the initial cytoreduction (tumor debulking) has a significant impact on patient outcomes. Surgeons must rely primarily on their visual and tactile senses, aided at times by static pre-operative images, to excise the cancer.
OTL38 is a novel compound consisting of a folic acid-targeting molecule, or ligand, linked to a near-infrared dye. The goal of this technology is to allow the surgeon to see, through the use of a NIR (near -infrared) camera, hard-to-detect, small cancer lesions or diseased lymph nodes that might otherwise be missed. OTL38 and our other proprietary compounds are designed to enhance the view in real time, and if proven successful, we believe may be an important addition to image-guided surgery.
Our goal; To use our ligands to precisely target overexpressed diseased tissue
Prove illuminating probes enable physicians to see with clarity
A small molecule designed with patients in mind
See how our tumor highlighting drug OTL38 works to enhance visualization of cancerous tissue.
Watch Dr. Low discuss how OTL ligands are changing the course of disease diagnosis and prognosis.
Watch Dr. Low's TEDx presentation discussing innovated ideas in the area of medicine and drug delivery precision needs.